Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

acexamic acid

Known as: N-acetylamino-6-hexanoic acid, 6-(acetylamino)hexanoic acid, Hexanoic acid, 6-(acetylamino)- 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
A 66-year-old woman, with stasis dermatitis, hypertension, and hypercholesterolemia, but no previous story of atopy, has been… Expand
2004
2004
SummaryThe acute toxicities of the cellular differentiating agent hexamethylene bisacetamide (HMBA) in humans and animals include… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 4
2004
2004
AbstractPurpose. The uptake of zinc as acexamic acid salt in the rat gastrointestinal tract, using an in situ static technique… Expand
1993
1993
Computer assisted quantitative structure-activity studies using comparative molecular field analysis (CoMFA) were performed on a… Expand
  • figure 2
  • figure 3
  • table I
  • table 2
  • figure 4
1991
1991
A Phase I clinical trial and pharmacological study of nasogastrically administered hexamethylene bisacetamide, a polar-planar… Expand
1989
1989
6-Acetamidohexanal has been identified in human plasma and urine as a metabolite of the cell-differentiating agent, hexamethylene… Expand
1988
1988
We studied the ability of five metabolites of hexamethylene bisacetamide (HMBA), which we had previously identified in patient… Expand
  • figure 1
  • table 1
  • table 5
  • table 3
  • table 4
1988
1988
We have previously demonstrated a number of metabolites of hexamethylene bisacetamide (HMBA) in the urine of patients treated… Expand
1988
1988
We investigated whether leukemic cell lines could convert hexamethylene bisacetamide (HMBA) to any of the metabolites previously… Expand
  • figure 1
  • table 2
  • table 3
1986
1986
Hexamethylene bisacetamide, a compound which in vitro induces differentiation in a wide variety of human and animal cancer cell… Expand
  • table 3
  • figure 2